Stocks in play: Irwin Naturals Inc
Announces it has entered into a non-binding amended and restated Letter of Intent for a business combination with Braxia Scientific Corp., a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders. The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares of Braxia. Irwin Naturals Inc shares C.IWIN are trading up $0.20 at $3.95.
Read:
Addressing the USA’s 200 to 1 Security Protection Gap is a Serious Concern for Tech Companies
Latest Set of FDA Fast Track Designations Causing Optimism in Biotech Sector
Biotech Sector to Unveil New Data and Developments at 2022 SABCS in San Antonio
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
New Biotech Sector Drug Combinations Target a Drop in Pancreatic Cancer Mortality Rates